News Conference News VIVA 2021 EMINENT: Better Patency With DES Over BMS for Fem-Pop Lesions L.A. McKeown October 12, 2021
News Conference News VIVA 2019 Calcium Conundrum: New Scores, Research Aim to Boost Outcomes in PAD Interventions L.A. McKeown November 13, 2019
News Conference News VIVA 2018 No Gender Difference in Patency Rates 1 Year After DCB for PAD: ILLUMENATE Substudy L.A. McKeown November 13, 2018
News Conference News VIVA 2018 Now You See Them, Now You Don’t: Bioresorbable Devices Target Large-Bore Closures and PE Prevention L.A. McKeown November 09, 2018
Presentation VIVA 2017 Is Aspirin Really a Class I Medication in Peripheral Artery Disease? Presenter: Ehrin J. Armstrong September 19, 2017
News Conference News VIVA 2017 Low-Dose Paclitaxel DCB Shows Long-term Durability in Treating PAD L.A. McKeown September 18, 2017
Presentation VIVA 2017 Results from the IN.PACT SFA Randomized Trial Presenter: Peter A. Schneider September 15, 2017
Presentation VIVA 2017 Two-year Results from the IN.PACT Global Study Presenter: Thomas Zeller September 14, 2017
Presentation VIVA 2017 Paclitaxel-Eluting Stent Treatment for PAD: Insights from the Zilver PTX Post-Market Study in Japan Presenter: Michael Dake September 14, 2017
News Conference News VIVA 2017 DCBs, Stents, and ‘Swirling Flow’ Show Promise in Femoropopliteal Disease L.A. McKeown September 13, 2017
News Conference News VIVA 2017 Apixaban May Be Better Choice Than Rivaroxaban for DVT Patients L.A. McKeown September 11, 2017
News Conference News VIVA 2016 Bioresorbable Scaffold Shows Sustained Promise in Superficial Femoral and Iliac Artery Lesions L.A. McKeown September 22, 2016
News Conference News VIVA 2016 Long PAD Lesions Respond Well to DCB, but Optimal Patient Selection Still Unclear L.A. McKeown September 21, 2016
News Conference News VIVA 2016 IVUS Improves Management of Iliofemoral Venous Stenting L.A. McKeown September 20, 2016